Pay in 4 interest-free payments of $27.00 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors
2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride
A769662 could be intraperitoneally (IP) dosed to mice at 30 mg/kg twice per day
Polyethylene glycol nonyl phenyl ether) are nonionic surfactants used as detergents
In MMTV-Wnt1 tumor models
Linifanib (ABT-869) - CAS# 796967-16-3 acin(DU 6859A) 2) as a CYP17 lyaseLinifanib, CAS No. 796967 16 3, also known as ABT 869, is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine threonine kinases. This agent does not have a
US$ 239.50
US$ 22.00
US$ 29.00
US$ 172.00
US$ 189.00
US$ 39.00
US$ 18.00
US$ 179.00